Arcturus Therapeutics Holdings (ARCT) closed FY 2025 with fourth quarter revenue of US$7.2 million and a basic EPS loss of US$1.03, while trailing 12 month revenue reached US$82.0 million alongside a basic EPS loss of US$2.40. Over recent quarters the company has seen revenue shift from US$41.7 million in Q3 2024 to US$29.4 million in Q1 2025, US$28.3 million in Q2 2025, US$17.2 million in Q3 2025 and US$7.2 million in Q4 2025, with quarterly basic EPS losses ranging between US$0.26 and US$1.11. With the stock trading at about US$8.90, these results keep the spotlight on how efficiently Arcturus is converting its revenue base into future margin improvement.

See our full analysis for Arcturus Therapeutics Holdings.

With the headline numbers on the table, the next step is to see how this earnings print lines up with the key narratives around Arcturus's growth potential, risk profile and path toward profitability.

TTM loss of US$65.8 million keeps profitability out of reach

• Over the trailing 12 months to Q4 2025, Arcturus reported total revenue of US$82.0 million and a net loss of US$65.8 million, with basic EPS at a loss of US$2.40, showing that the revenue base is not yet large enough to cover current operating costs.
• Bears highlight that, despite this revenue, Arcturus is forecast to remain unprofitable over the next three years. The recent quarterly pattern of losses, from US$6.9 million in Q3 2024 to US$30.0 million in Q4 2024 and US$29.1 million in Q4 2025, supports concerns that earnings rely heavily on successful commercialization of a narrow pipeline.
  • Critics point to the FY 2025 quarterly net losses, which ranged from about US$9.2 million in Q2 to US$29.1 million in Q4, as evidence that even when revenue was US$28.3 million to US$29.4 million in early 2025, the business still produced sizeable losses.
  • The bearish narrative also flags that collaboration related revenue has fallen compared to the prior year period, so without stronger new commercial revenue to replace it, the company may continue to report similar loss levels on a trailing 12 month basis.

On these figures, skeptics argue that any path to profitability will depend on both higher revenue than the US$82.0 million reported over the last year and tighter control of expenses tied to the current loss profile, before they would see evidence of a self funding model emerging. 🐻 Arcturus Therapeutics Holdings Bear Case

P/S of 3.1x sits well below biotech peers

• Arcturus trades on a trailing P/S ratio of about 3.1x, compared with a peer average of roughly 9.2x and a US biotechs industry average of about 10.9x, so investors are currently paying a much smaller multiple of sales than for many comparable stocks.
• Bulls argue that this lower P/S multiple, paired with an average 21.9% annual revenue growth rate and a 20.4% yearly reduction in losses over the past five years, lines up with a view that the stock price of US$8.90 does not fully reflect the potential earnings power if the pipeline translates into higher margin revenue.
  • Supporters point out that trailing 12 month revenue of US$82.0 million sits against a market value that implies 3.1x sales, while analysts collectively see scope for revenue growth of roughly 21.9% per year, which they see as a mismatch between growth and valuation multiples.
  • At the same time, the consensus analyst price target of US$23.30 is above the current share price of US$8.90, and bullish analysts link this gap to expectations that narrowing losses and higher sales could eventually compress that valuation discount if forecasts play out.

If you want to see how supporters connect these earnings trends to a more optimistic long term story, have a closer look at the 🐂 Arcturus Therapeutics Holdings Bull Case

Revenue growth meets a still loss making pipeline

• Management and analysts highlight that trailing 12 month revenue has been growing at about 21.9% per year and losses have shrunk at roughly 20.4% per year over five years, yet the company still recorded a trailing loss of US$65.8 million and is expected to remain loss making over at least the next three years.
• What stands out is how this mix of growth and losses fits both bullish and bearish storylines. Bulls point to the growing revenue base and a pipeline that now includes two Phase I and two Phase II products, while bears focus on the concentration of that pipeline and the fact that no DCF fair value could be produced from the available data.
  • Supportive investors tend to focus on the presence of multiple clinical stage assets alongside the shrinking losses trend, arguing that this offers more ways for the revenue line to build beyond the US$82.0 million reported over the last year.
  • Skeptics counter that the absence of a DCF fair value estimate, combined with forecasts that do not show profitability in the next three years, means the current growth and pipeline mix has not yet translated into a clearly quantifiable long term earnings profile.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Arcturus Therapeutics Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both optimism and caution in this story, it helps to look past the headlines, review the full data set yourself and weigh up the 2 key rewards and 1 important warning sign in the 2 key rewards and 1 important warning sign.

See What Else Is Out There

Arcturus is still generating sizeable losses, with a trailing 12 month net loss of US$65.8 million and no clear near term path to profitability.

If you want stocks where earnings are less of a concern right now, start comparing companies highlighted in the 72 resilient stocks with low risk scores to balance out your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.